Celera Genomics Group-an Applera Corp. Business Publishes Data Validating Cirrhosis Risk Score as a Predictor of Cirrhosis in Chronic Hepatitis C Patients
27 Apr 2007
ROCKVILLE, Md.--(BUSINESS WIRE)--Celera (NYSE: CRA), an Applera Corporation business, today announced the publication of data from a research study validating its multi-gene Cirrhosis Risk Score (CRS) that predicts future risk of developing cirrhosis in patients with chronic hepatitis C (CHC). This paper is scheduled to appear in the August 2007 edition of Hepatology, published on behalf of the American Association for the Study of Liver Diseases, and is expected to be available on the publication’s website at The lead author of this paper was Hongjin Huang, Ph.D., Associate Director, Liver Diseases, at Celera.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.